Compare Ishares Msci Italy ETF (EWI) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? Ishares Msci Italy ETF trades at $56.06 (market cap $1.20B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 8.5× Ishares Msci Italy ETF's market cap, and Ishares Msci Italy ETF is more actively traded (332,777 versus 1,108,124). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 55 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EWI | GMED | |
|---|---|---|
Market Cap | $1.20B | $10.25B |
Volume | 332,777 | 1,108,124 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $96.82 |
52-Week Low | $50.47 | $58.33 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.66 with a 0.87% daily gain. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral with RSI levels suggesting potential oversold conditions. The ETF offers concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU-supported infrastructure investments.
The outlook remains cautious due to eurozone economic pressures and ECB tightening, but EWI provides strategic access to Italy's banking and infrastructure investment cycle. Key risks include eurozone business confidence declines and energy price volatility. Analyst sentiment is mixed with technical weakness offset by long-term structural opportunities in Italian markets.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
